Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

Konstantinidis, Lazaros; Mantel, Irmela; Pournaras, Jean-Antoine; Zografos, Léonidas; Ambresin, Aude

doi:10.1007/s00417-008-0995-0

Cited by 69 publications

(64 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The dose was chosen in accordance with the product labelling for treatment of AMD 15 and the dose level used in several recent case series in myopic CNV. [16][17][18][19] The initial dose was followed by repeated injections, administered as needed (PRN) following monthly monitoring with Spectral Domain Optical Coherence Tomography (SD OCT), but no more frequently than every 28 days, for upto a further 11 months. The algorithm used to determine the need for retreatment is presented in Figure 1.…”

Section: Patients and Designmentioning

confidence: 99%

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Tufail

Patel

Sivaprasad

et al. 2013

Eye

View full text Add to dashboard Cite

Aims To evaluate the efficacy and safety of intravitreal ranibizumab in patients with choroidal neovascularisation secondary to pathological myopia (myopic CNV). Data are from a pre-planned, 6-month interim analysis. Methods Phase II, open-label, single arm, multicentre, 12-month study, recruiting patients (aged Z18 years) with active primary or recurrent subfoveal or juxtafoveal myopic CNV, with a best-corrected visual acuity (BCVA) score of 24-78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the study eye and a diagnosis of high myopia of at least À 6 dioptres. Patients received 0.5 mg ranibizumab administered intravitreally to the study eye, followed by monthly injections given as needed (based on a predefined algorithm) for up to 11 months. Results At 6 months, mean BCVA improved from baseline by 12.2 letters, as did central macular thickness (in this interim analysis defined as a measure of either central subfield macular thickness or centre point macular thickness) from baseline by 108 mm in the 48 study eyes of 48 patients. Fewer patients had centre-involving intraretinal oedema (13.0% vs 91.5%), intraretinal cysts (10.9% vs 57.4%), or subretinal fluid (13.0% vs 66.0%) at 6 months than at baseline. Patients received a mean of 1.9 retreatments, were satisfied with ranibizumab treatment, and well being was maintained. No new safety signals were identified. Conclusions Results from the planned interim analysis support the role of ranibizumab in the treatment of myopic CNV, with excellent efficacy achieved with a low number of injections and few serious adverse events.

show abstract

Section: Patients and Designmentioning

confidence: 99%

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Tufail

Patel

Sivaprasad

et al. 2013

Eye

View full text Add to dashboard Cite

show abstract

“…There are two published reports on ranibizumab and one for pegaptanib sodium treatment. [21][22][23] Treatment outcomes after intravitreal bevacizumab in 15 studies are summarised in Table 1. [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] A cumulative analysis of all study data reveals the following trends.…”

Section: Pathological Myopiamentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

“…9,12,31 A sua eficácia e segurança estão descritas em vários estudos retrospectivos e em alguns ensaios clínicos prospectivos. Assim, temos assistido ao uso difundido destes agentes no tratamento da neovascularização coroideia associada tanto à MP como à DMI, com melhorias funcionais e anatómicas significativas.…”

Section: Discussionunclassified

“…33 Desenvolvido especificamente para uso intraocular, apresenta algumas vantagens teóricas relativamente ao bevacizumab, nomeadamente o menor peso molecular, associado a uma melhor e mais rápida penetração nas camadas da retina, maior afinidade para o recetor VEGF-A e menor incidência de efeitos sistémicos. 12 O bevacizumab é um anticorpo monoclonal, humanizado, recombinante, 33 desenvolvido para tratamento endovenoso, como adjuvante da quimioterapia, na terapia de neoplasias sólidas metastizadas. Assume particular interesse no tratamento da NVC na miopia, pelos resultados promissores descritos em séries de casos e alguns ensaios clínicos, 1,6,8,11,13,[34][35][36] aliados a um preço significativamente mais baixo quando comparado com o ranibizumab, permitindo deste modo que a terapêutica seja acessível a um maior número de doentes.…”

Section: Discussionunclassified

“…3,11 De facto, estudos demonstraram que os níveis de VEGF se encontram aumentados no humor aquoso dos doentes com neovascularização ativa, quer na degenerescência macular da idade (DMI), quer na miopia patológica. 12 Como opções terapêuticas para a NVC, foram já usadas fotocoagulação a laser, cirurgia submacular, radioterapia e translocação da mácula. Contudo, os resultados obtidos são variáveis, estando associados a elevadas taxas de recorrência e perda visual progressiva, não permitindo, deste modo, estabelecer um benefício global.…”

Section: Introductionunclassified

See 1 more Smart Citation

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

et al. 2014

View full text Add to dashboard Cite

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes. Material and Methods:In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment. Results:The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9µm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001). Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

show abstract

Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization

Abstract: In this small series of eyes with limited follow-up, intravitreal ranibizumab was a safe and effective treatment for CNV secondary to PM, resulting in functional and anatomic improvements.

Cited by 69 publications

References 40 publications

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

Contact Info

Product

Resources

About